Downward price corrections across pharmaceutical equities are frequently triggered by a combination of sector-specific headwinds, including unexpected clinical trial setbacks, regulatory scrutiny from health authorities, patent expiration cliffs, and legislative pricing pressures. Furthermore, macroeconomic shifts—such as rising interest rates drawing capital toward risk-free assets or broader market rotations away from defensive healthcare sectors—can induce short-term selling pressure across both large-cap pharmaceutical giants and small-cap biotech firms.